InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,455.59
(
-0.32%
)
US TECH 100
19,222.39
(
-0.19%
)
Dow Jones
39,195.08
(
0.15%
)
Brent Oil
84.91
(
-0.11%
)
Bitcoin
63,415.33
(
-2.17%
)
Post# of 216
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TREND1

Send PM Follow Ignore
Followers 416
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

TREND1

Member Level

Re: None

Wednesday, 08/31/2016 12:11:06 PM

Wednesday, August 31, 2016 12:11:06 PM

Post# of 216
Micro cap MannKind (MNKD +13.4%) tries to regain some ground after its recent sell-off on the news that it is working on a less-costly alternative to Mylan's (MYL -1.1%) EpiPen (epinephrine injection, USP). CEO Matt Pfeffer says his firm is working on an inhalable formulation of the allergic reaction medication that will be "much cheaper" than Mylan's branded product. He adds that the company has been working on the project for some time and it considers it its lead program.

MannKind expects to file an IND in early next year. It needs to do something. Inhaled insulin Afrezza has been a complete flop.

MAIN BOARD http://investorshub.advfn.com/TRADING-3X-ETFs-TNA-NUGT-ETC-12981/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up